BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger August 3, 2026Posted inBiotechnology BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso. Post navigation Previous Post How the Brain Sustains MotivationNext PostFoundation Model Uses Sleep Data to Predict Health Risks and Clinical Outcomes